{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-130419","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.419950+00:00","generated_at":"2026-05-15T08:26:08.010443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"confidence":"high","headline":"Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement","bullets":["Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.","Cash and marketable securities $21.2M at Dec 31, 2025, down from $41.3M at Dec 31, 2024.","Completed acquisition of Faeth Therapeutics; adds oral PIKTOR candidate targeting PI3K/AKT/mTOR.","Concurrent $200M private placement supports Phase 2 endometrial and Phase 1b breast cancer trials.","Topline data from Phase 2 endometrial and start of Phase 1b breast cancer expected by year-end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-130419","json":"https://secwatch.observer/filing/0001193125-26-130419.json","markdown":"https://secwatch.observer/filing/0001193125-26-130419.md","text":"https://secwatch.observer/filing/0001193125-26-130419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/0001193125-26-130419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/d118677d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:26:08.010443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}